Literature DB >> 1985708

Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma.

B E Powers1, S J Withrow, D E Thrall, R C Straw, S M LaRue, R L Page, E L Gillette.   

Abstract

The percent tumor necrosis was determined in 200 dogs with spontaneously occurring osteosarcoma. One hundred dogs had no treatment before amputation or death. One hundred other dogs were treated with either radiation therapy alone (n = 23), intraarterial (IA) cisplatin alone (n = 16), intravenous (IV) cisplatin alone (n = 6), radiation therapy plus IA cisplatin (n = 47), or radiation therapy plus IV cisplatin (n = 8). Eighty-nine of these 100 dogs had their tumors resected 3 weeks after the end of therapy (6 weeks after the initiation of therapy) and replaced with a cortical bone allograft. Dogs with preoperative treatment were evaluated for local tumor control and time to metastasis. The mean percent tumor necrosis in untreated osteosarcoma was 26.8%. The mean percent tumor necrosis for dogs receiving radiation only, IA cisplatin only, and IV cisplatin only was 81.6%, 49.1% and 23.8%, respectively. The mean percent tumor necrosis for dogs receiving radiation therapy plus IA cisplatin or radiation therapy plus IV cisplatin was 83.7% and 78.2%, respectively. There was no significant difference between percent tumor necrosis in untreated osteosarcoma compared with those receiving IV cisplatin, but there was a significant increase in percent tumor necrosis with all other treatments. A mathematic model for the effect of cisplatin and radiation dose was developed using multiple regression analysis. The radiation dose calculated to cause at least 80% tumor necrosis was 42.2 Gy (95% confidence interval [CI], 38.0 to 47.6 Gy) when radiation was given alone and 28.1 Gy (95% CI, 21.3 to 36.6 Gy) when radiation was combined with IA cisplatin. Areas of viable tumor tended to be most frequent adjacent to the articular cartilage and in the joint capsule. Percent tumor necrosis was strongly predictive for local tumor control; 28 of 32 dogs with greater than 80% tumor necrosis had local control, and only eight of 29 dogs with less than 79% tumor necrosis had local control (P = 0.0047). There was no correlation between percent tumor necrosis and time to metastasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985708     DOI: 10.1002/1097-0142(19910101)67:1<126::aid-cncr2820670123>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.

Authors:  Qian Yin; Li Tang; Kaimin Cai; Rong Tong; Rachel Sternberg; Xujuan Yang; Lawrence W Dobrucki; Luke B Borst; Debra Kamstock; Ziyuan Song; William G Helferich; Jianjun Cheng; Timothy M Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

Review 2.  Treatment recommendations for osteosarcoma and adult soft tissue sarcomas.

Authors:  P Picci; S Ferrari; G Bacci; F Gherlinzoni
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

3.  Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.

Authors:  Daniel L Gustafson; Keagan P Collins; Jared S Fowles; E J Ehrhart; Kristen M Weishaar; Sunetra Das; Dawn L Duval; Douglas H Thamm
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-14       Impact factor: 3.333

4.  Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.

Authors:  Jaime F Modiano; Donald Bellgrau; Gary R Cutter; Susan E Lana; Nicole P Ehrhart; Ej Ehrhart; Vicki L Wilke; J Brad Charles; Sibyl Munson; Milcah C Scott; John Pozniak; Cathy S Carlson; Jerome Schaack; Richard C Duke
Journal:  Mol Ther       Date:  2012-07-31       Impact factor: 11.454

Review 5.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

6.  Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs.

Authors:  Tiffany Wormhoudt Martin; Lynn Griffin; James Custis; Stewart D Ryan; Mary Lafferty; Mary-Keara Boss; Daniel Regan; Sangeeta Rao; Del Leary; Stephen J Withrow; Susan M LaRue
Journal:  Vet Comp Oncol       Date:  2021-01-13       Impact factor: 2.385

7.  Fracture rate and time to fracture in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: A single institution study.

Authors:  Carissa J Norquest; Charles A Maitz; Deborah A Keys; Melanie Moore; Jeffrey N Bryan; Tara J Ehling; Jimmy C Lattimer; Brian K Flesner
Journal:  Vet Med Sci       Date:  2022-03-08

8.  Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.

Authors:  Ryan C Curtis; James T Custis; Nicole P Ehrhart; E J Ehrhart; Keith W Condon; Sara E Gookin; Seth W Donahue
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

9.  Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.

Authors:  Bernhard Robl; Sander Martijn Botter; Giovanni Pellegrini; Olga Neklyudova; Bruno Fuchs
Journal:  J Exp Clin Cancer Res       Date:  2016-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.